Infiltrating Tumor Border Configuration is a Poor Prognostic Factor in Stage II and III Colon Adenocarcinoma

2020 ◽  
Author(s):  
Yasmeen Z. Qwaider ◽  
Naomi M. Sell ◽  
Caitlin E. Stafford ◽  
Hiroko Kunitake ◽  
James C. Cusack ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Colon Adenocarcinoma ◽  
Stage Ii ◽  
Poor Prognostic Factor

Micrometastasis volume in stage II colorectal cancer: A prospective study by Clinical Study Group of Osaka University (CSGO).

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 597-597
Author(s):  
Kohei Murata ◽  
Hirofumi Yamamoto ◽  
Mutsumi Fukunaga ◽  
Tadashi Ohnishi ◽  
Shingo Noura ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factor ◽  
Cox Regression ◽  
Stage Ii ◽  
Significant Prognostic Factor ◽  
Rt Pcr ◽  
Clinical Value ◽  
Poor Prognostic Factor ◽  
Stage Ii Colorectal Cancer ◽  
Cea Mrna

597 Background: We reported in a retrospective study that the presence of micrometastasis in lymph nodes (LNs), when assessed by CEA-specific RT-PCR, is a significant prognostic factor in stage II colorectal cancer (CRC). The aim of this study was to clarify the clinical value of micrometastasis in a prospective multicenter trial. Methods: From November 2001 to December 2005, a total of 419 CRC cases were preoperatively registered at a central data center. Of them, 315 node-negative stage II CRC were enrolled. After RNA quality check, 304 CRC cases were analyzed for CEA mRNA in LNs by both conventional RT-PCR (a band method) and quantitative RT-PCR. Long-term prognosis of the patients was determined by each method. Results: A positive band for CEA mRNA was detected in 73 (24.0%) of 304 patients. Post-operative adjuvant chemotherapy was applied in 31 CEA band-positive cases with an oral 5-FU derivative HCFU (1-hexylcarbamoyl-5-fluorouracil) for one year, while chemotherapy was not administered to CEA band-negative group. Multivariate Cox regression analyses revealed that a high micrometastasis volume (High-MMV, n = 95) was an independent poor prognostic factor for 5-year DFS ( P= 0.001) and 5-year OS ( P= 0.016). Conclusions: This prospective clinical trial demonstrates that micrometastasis volume is a useful marker in identifying patients who are at high or low risk for recurrence of stage II CRC.

scholarly journals Low proliferative level is a poor prognostic factor for colon adenocarcinoma

2014 ◽  
Vol 95 (3) ◽  
pp. 378-382
Author(s):  
G A Raskin ◽  
S V Petrov
Keyword(s):  
Prognostic Factor ◽  
Proliferative Activity ◽  
Single Case ◽  
Cancer Recurrence ◽  
Colon Adenocarcinoma ◽  
Tumor Stage ◽  
Ki 67 ◽  
Poor Prognostic Factor ◽  
Significant Difference ◽  
Primary Colon

Aim. To match up the proliferative activity of colon adenocarcinoma cells with tumor stage and survival rate. Methods. Ki-67 protein expression was evaluated by immunohistochemical methods in 217 patients with primary colon adenocarcinoma. After epitope retrieval and endogenous peroxidase inhibiting by 3% solution of hydrogen peroxide, histologic samples were stained by antibodies to Ki-67 protein (clone SP6, dilution 1:300) and polymer systemic detection with diaminobenzidine as a chromogenic substrate. Nuclear counterstain was performed using Mayer’s hematoxylin solution. Results. Assessment of colon adenocarcinoma proliferative activity showed a significant difference between the number of cases with high (70%) and relatively low (≤30%) proliferative levels in groups with metastatic cancers and non-metastatic tumors. In patients with no relapses, colon adenocarcinoma proliferative activity assessment showed proliferation level exceeding 70% in 21 (95%) out of 22 cases, in a single case proliferation level of 60% was found according to Ki-67, no cases of proliferation level lower than 50% was found. Statistical analysis showed that proliferative activity was significantly lower in patients with metastatic colon adenocarcinoma compared to cases of adenocarcinoma without metastases (p= 0.0019). We observe one clinical case of aggressive colon adenocarcinoma with omental, peritoneal, paraumbilical metastases in 28-year old patient, in whom proliferative activity by Ki-67 was measured as 20%. Conclusion. Low proliferative level in colon adenocarcinoma is a poor prognostic factor for possible metastasing and cancer recurrence.

scholarly journals Expression of aquaporin-1 is a poor prognostic factor for stage II and III colon cancer

2013 ◽  
Vol 1 (6) ◽  
pp. 953-958 ◽  
Author(s):  
TORU YOSHIDA ◽  
SHOZO HOJO ◽  
SHINICHI SEKINE ◽  
SHIGEAKI SAWADA ◽  
TOMOYUKI OKUMURA ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factor ◽  
Stage Ii ◽  
Poor Prognostic Factor ◽  
Aquaporin 1

scholarly journals Significance of neutrophil-lymphocyte ratio (NLR) as a prognostic factor in Stage II colorectal cancer

2020 ◽  
Author(s):  
Masano Sagawa ◽  
HAJIME YOKOMIZO ◽  
KAZUHIKO YOSHIMATSU ◽  
SACHIYO OKAYAMA ◽  
YASUHUMI YAMADA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Factors ◽  
Prognostic Factor ◽  
Disease Free Survival ◽  
Cox Proportional Hazards Model ◽  
Stage Ii ◽  
Poor Prognostic Factor ◽  
Neutrophil Lymphocyte Ratio ◽  
Lymphocyte Ratio ◽  
Stage Ii Colorectal Cancer

Objective : To evaluate the significance of preoperative neutrophil-lymphocyte ratio (NLR) for the analysis of disease-free survival (DFS) and overall survival (OS) in patients with stage II colorectal cancer (CRC).Summary of Background Data: Previous reports have indicated the association of NLR with a poor prognosis and tumor progression in patients with CRC. However, the role of NLR as a prognostic marker specifically in patients with stage II CRC has not been well studied.Methods : A total of 124 colon cancer patients were included in the study. The OS and DFS of patients were compared using preoperative NLR. Univariate and multivariate analyses using the Cox proportional hazards model were performed to determine the prognostic value of NLR.Results : The OS and DFS of patients with an NLR ≥ 4.0 were significantly lower when compared with those of patients with an NLR< 4.0. Multivariate analysis showed that NLR ≥ 4.0, PS score ≥ 1, and depth of tumor invasion T4 were independent prognostic factors for DFS, whereas age above 80 years, NLR ≥ 4.0, and PS score ≥ 1 were independent prognostic factors for OS.Conclusions : NLR can be considered a poor prognostic factor in patients with stage II CRC after curative surgery.

Epidermal growth factor receptor (EGFR) as a prognostic factor over 10 years in non-metastasic colon carcinoma (NMCC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21062-21062
Author(s):  
C. Pericay ◽  
C. Santos-Vivas ◽  
E. Pous-Saltor ◽  
T. Bonfill-Abella ◽  
E. Dotor-Navarro ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Growth Factor Receptor ◽  
Progression Free Survival ◽  
Stage Ii ◽  
Stage Iii ◽  
Primary Adenocarcinoma ◽  
Metastatic Colon Cancer ◽  
Curative Surgery ◽  
Poor Prognostic Factor

21062 Background: EGFR is a protooncogen that facilitates metastasis in cancer. It is overexpressed in colorectal carcinoma in 40% to 80%, and correlates a worse prognosis. Aim: To find patterns of EGFR overexpression in NMCC and to correlate these patterns with the follow-up. Methods: We analized NMCC with a selection criteria: 1. primary adenocarcinoma of the colon, without metastasis and with curative surgery, 2. pT3 pN0–2 pM0, progression-free in the first 6 months postsurgery, 3. initial follow-up began 6 months postsurgery, 4. minimum follow-up over 5 years. Dako PharmaDx kit (Glostrup, Denmark) was used for immunohistochemical study for EGFR. Dako staining and A431-AAM cells were used as positive control. Immunoreactivity for membrane (1(+), 2(+) and 3(+) intensity) and for cytoplasma was evaluated. Proportions of immunostained cells were also assessed. Results: 195 patients (p) were eligible. Year of diagnosis: 1994: 1p; 1995: 4p; 1996: 20p; 1997: 29p; 1998: 33p; 1999: 36p; 2000: 34p; 2001: 38p. Male/female: 93/102; Mean age: 71 years (28- 94). Location: 116/79 left/right. Stage II/III: 125/70. EGFR membrane positivity: 84/195 cases (43%), 49/125 (39%) in Stage II and 35/70 (50%) in Stage III. With a median follow-up of 7 years: Stage II: 29/125 relapsed (EGFR±: 12(24%)/17(22%)). Stage III: 33/70 relapsed (EGFR± : 21(60%)/12(34%)). EGFR membrane positivity was a poor prognostic factor with a significant progression-free survival (PFS) (p=0.042) and a non-significant overall survival (OS) (p=0.066). When follow-up period was increased over 10 years (patients from 1994 to 1998), EGFR membrane positivity maintained its poor prognostic factor in PFS (p=0.009) and presented a significant OS (p=0.02). Non-significant differences were found in immunostaining ratios. Conclusions: In patients with non-metastatic colon cancer, EGFR membrane positivity was a tumor progression prognostic factor, and this poor prognosis was maintained over time. Study supported by a grant from C.I.R. Hospital de Sabadell. Consorci Sanitari Parc Taulí. Sabadell and a grant from Merck Laboratory. No significant financial relationships to disclose.

Prognostic role of aberrant mTOR activation in patients with stage II and III colorectal cancer

2020 ◽  
Vol 14 (12) ◽  
pp. 1127-1137
Author(s):  
Tong-Tong Zhang ◽  
Yi-Qing Zhu ◽  
Hong-Qing Cai ◽  
Jun-Wen Zheng ◽  
Jia-Jie Hao ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cox Regression ◽  
Disease Free Survival ◽  
Stage Ii ◽  
Poor Prognostic Factor ◽  
Cox Regression Analysis ◽  
Kaplan Meier ◽  
Potential Biomarker ◽  
Risk Predictor

Aim: This study aimed to develop an effective risk predictor for patients with stage II and III colorectal cancer (CRC). Materials & methods: The prognostic value of p-mTOR (Ser2448) levels was analyzed using Kaplan–Meier survival analysis and Cox regression analysis. Results: The levels of p-mTOR were increased in CRC specimens and significantly correlated with poor prognosis in patients with stage II and III CRC. Notably, the p-mTOR level was an independent poor prognostic factor for disease-free survival and overall survival in stage II CRC. Conclusion: Aberrant mTOR activation was significantly associated with the risk of recurrence or death in patients with stage II and III CRC, thus this activated proteins that may serve as a potential biomarker for high-risk CRC.

scholarly journals Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1796
Author(s):  
Markus Eckstein ◽  
Verena Lieb ◽  
Rudolf Jung ◽  
Danijel Sikic ◽  
Katrin Weigelt ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Prognostic Factor ◽  
Tumor Cells ◽  
Immune Cells ◽  
Potential Candidate ◽  
Poor Prognostic Factor ◽  
Risk Of Death ◽  
Increased Risk ◽  
Muscle Invasive ◽  
Disease Specific

Urothelial bladder cancer (BCa) is the ninth most commonly diagnosed cancer worldwide and accounts for approximately 3% of global cancer diagnoses. We are interested in prognostic markers that may characterize tumor cells (TCs) and immune cells (ICs) and their relationship in BCa. A potential candidate marker that meets these criteria is progranulin (GP88), which is expressed separately in TCs and ICs. We analyzed GP88 expression by immunohistochemistry (IHC) in 196 muscle-invasive BCa samples using a tissue microarray. The immunoreactive score for GP88 staining in TCs and the percentage of GP88-positive ICs was determined. An easy cutoff for the staining status of TCs (positive vs. negative) and ICs (0% vs. >0%) and, more generally, negative vs. positive GP88 staining could be applied. We detected 93 patients (47.4%) and 92 patients (46.9%) with GP88-positive TCs or ICs, respectively. The IHC results were correlated with clinicopathological and survival data. Positive GP88 staining in TCs appeared to be an independent poor prognostic factor for disease-specific survival (DSS) (RR (relative risk) = 1.74; p = 0.009) and recurrence-free survival (RFS) (RR = 1.92; p = 0.002). In contrast, negative GP88 staining in ICs was an independent negative predictor for overall survival (OS) (RR = 2.18; p < 0.001), DSS (RR = 2.84; p < 0.001) and RFS (RR = 2.91; p < 0.001) in multivariate Cox’s regression analysis. When combining GP88 staining in TCs and ICs, a specific combination of GP88-positive TCs and GP88-negative ICs was associated with a 2.54-fold increased risk of death, a 4.21-fold increased risk of disease-specific death and a 4.81-fold increased risk of recurrence compared to GP88-negative TCs and GP88-positive ICs. In summary, GP88 positivity in TCs is a negative prognostic factor for DSS and RFS. In addition, GP88 positivity can mark ICs that are associated with a good prognosis (OS, DSS and RFS). The combination of GP88 staining in TCs and ICs appears to be a significant independent prognostic biomarker in muscle-invasive BCa.

Sign in / Sign up

Export Citation Format

Share Document